Physician profile
Jason W Brooks
NPI 1164465712
$3,545.84
in general payments reported to CMS, 2019-2025
30 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $133 · 2021: $506 · 2022: $737 · 2023: $619 · 2024: $704 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,066.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $376.17 | 2019-2025 | Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $372.57 | 2022-2024 | Caplyta |
| Abbvie INC. | $344.34 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $245.71 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $127.45 | 2019 | |
| Pfizer INC. | $121.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.70 | 2019-2022 | |
| Exact Sciences Corporation | $89.37 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $80.25 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $67.94 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.39 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.36 | 2019-2021 | |
| Amgen INC. | $54.88 | 2024 | Evenity, Prolia |
| Biohaven Pharmaceuticals, INC. | $47.58 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.25 | 2022 | |
| Acadia Pharmaceuticals INC | $28.87 | 2024 | Daybue |
| Azurity Pharmaceuticals, INC. | $23.00 | 2023 | Horizant |
| Idorsia Pharmaceuticals US INC | $22.67 | 2022 | |
| Antares Pharma, INC. | $21.90 | 2022 | |
| Mylan Specialty L.P. | $20.81 | 2023 | Yupelri |
| Allergan, INC. | $19.17 | 2020 | |
| Sanofi Pasteur INC. | $18.69 | 2021 | |
| Astellas Pharma US INC | $17.69 | 2019 | |
| Amarin Pharma, INC. | $17.28 | 2021 | |
| Alkermes, INC. | $17.20 | 2021 | |
| Nevro Corp. | $16.86 | 2024 | Senza |
| Eisai INC. | $14.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.